<DOC>
	<DOCNO>NCT02813837</DOCNO>
	<brief_summary>This single arm , open-label , multi-center clinical trial study CD19 target chimeric antigen receptor T cell therapy treat patient CD19 positive malignant B-cell derive leukemia lymphoma relapse ( stem cell transplantation chemotherapy ) refractory chemotherapy .</brief_summary>
	<brief_title>Chimeric Antigen Receptor T Cells ( CART ) Therapy Refractory/Relapsed B Cell Hematologic Malignancies</brief_title>
	<detailed_description>This single arm , open-label , multi-center clinical trial study CD19 target chimeric antigen receptor T cell therapy treat patient CD19 positive malignant B-cell derive leukemia lymphoma relapse ( stem cell transplantation chemotherapy ) refractory chemotherapy . When patient enroll trial , autologous CD19CART cell generate mononuclear cell patient 's peripheral blood ( PB ) . During term cell preparation CD19CART cell , patient receive condition regimen . One day complete condition regimen , patient give infusion CD19CART cell vein period 1 3 day . Patients monitor response , toxic effect , expansion persistence circulate CD19CART cell .</detailed_description>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<criteria>Patients diagnose CD19 positive refractory relapse B cell hematologic malignancy include acute lymphoblastic leukemia ( ALL ) , chronic lymphocytic leukemia ( CLL ) , nonHodgkin 's lymphoma ( NHL ) eligible appropriate autoHSCT alloHSCT relapse hematopoietic stem cell transplant ( HSCT ) At least one measurable lesion define one lesion large 1.5cm two lesion 1.0cm ( patient NHL ) Age ≤60 year Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 2 , Expected survival &gt; 6 month Left Ventricular Ejection Fraction ( LVEF ) ＞ 50 % history malignancy ; serious disease conflict treatment present trial All patient consent adopt efficient contraception method treatment treatment . The pregnant test woman child bear period negative treatment . patient understand willing participate trial . Inform consent form suppose obtain treatment Diagnosis classification undefined Those primary central nervous system lymphoma testicular leukaemia lymphoma Patients known history prior diagnosis epilepsia disease affect central nervous system , serious mental disease ; Patients secondary leukaemia lymphoma chemotherapy radiotherapy malignancy Active acute chronic graftversushost disease ( GVHD ) require systemic therapy , concurrent use immunosuppressant medication Class III/IV cardiovascular disability accord New York Heart Association Classification Pregnant lactate woman ( safety therapy unborn child know ) With active infection Active hepatitis B , hepatitis C syphilis infection Patients use systemic steroid within 2 week . Recent current use inhale steroid exclusionary Prior treatment gene therapy product Cluster differentiation 3 ( CD3 ) positive cell &lt; 0.9x10^4/ml peripheral blood ( PB ) Organ function meeting follow criterion : liver renal function : alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) ＞ 3 time upper limit normal , bilirubin &gt; 2.0 mg/dl（34.2umol/L） , creatinine ＞2.5mg/dl（221.0umol/L） ; hematopoietic function : Neutrophil count &lt; 1.0x10^9/L，hemoglobin &lt; 80g/L，platelet &lt; 50x10^9/L ( patient NHL ) Any uncontrolled active medical disorder would preclude participation outline HIV infection The researcher consider unsuitable participate clinical study . Patients poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>CD19+</keyword>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
</DOC>